United Net Income vs Capital Expenditures Analysis

UTHR Stock

USD 372.89 5.53 1.51%

United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Net Income and its Capital Expenditures accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Net Income vs Capital Expenditures

Net Income vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Net Income account and Capital Expenditures. At this time, the significance of the direction appears to have strong relationship.

The correlation between United Therapeutics' Net Income and Capital Expenditures is 0.71. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Net Income and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of United Therapeutics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Net Income i.e., United Therapeutics' Net Income and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in United Therapeutics financial statement analysis. It represents the amount of money remaining after all of United Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Capital Expenditures

Capital Expenditures are funds used by United Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of United Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Enterprise Value Over EBITDA is relatively stable compared to the past year. As of 11/25/2024, Enterprise Value Multiple is likely to grow to 10.85, while Discontinued Operations is likely to drop 5,600.

	2021	2022	2023	2024 (projected)
Gross Profit	1.6B	1.8B	2.1B	2.2B
Total Revenue	1.7B	1.9B	2.3B	2.4B

Gross Profit Total Revenue

United Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Good Will	Common Stock Total Equity	Short Term Investments	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.84	0.71	0.64	1.0	0.97	-0.14	0.97	-0.22	0.85	0.99	0.33	0.92	0.74	0.24	0.56	0.89	-0.3	0.89	0.99	0.92	0.46	0.95	0.99	0.83	0.48
Short Long Term Debt Total	0.84		0.5	0.37	0.8	0.8	0.26	0.8	-0.25	0.61	0.86	0.2	0.9	0.43	0.13	0.82	0.77	-0.3	0.92	0.8	0.84	0.4	0.82	0.79	0.82	0.51
Other Current Liab	0.71	0.5		0.29	0.72	0.67	-0.35	0.76	-0.05	0.71	0.68	0.5	0.65	0.78	0.16	0.4	0.63	-0.45	0.54	0.71	0.6	0.41	0.59	0.68	0.74	0.27
Total Current Liabilities	0.64	0.37	0.29		0.63	0.69	-0.31	0.57	-0.19	0.61	0.63	0.23	0.36	0.69	0.45	-0.09	0.56	0.02	0.58	0.62	0.48	0.42	0.53	0.65	0.47	0.24
Total Stockholder Equity	1.0	0.8	0.72	0.63		0.96	-0.19	0.98	-0.22	0.86	0.98	0.33	0.9	0.74	0.2	0.51	0.88	-0.31	0.85	0.99	0.91	0.42	0.95	0.99	0.81	0.47
Property Plant And Equipment Net	0.97	0.8	0.67	0.69	0.96		-0.18	0.94	-0.15	0.85	0.96	0.43	0.86	0.79	0.4	0.53	0.84	-0.31	0.9	0.96	0.92	0.61	0.88	0.96	0.82	0.55
Net Debt	-0.14	0.26	-0.35	-0.31	-0.19	-0.18		-0.26	0.12	-0.59	-0.04	-0.57	-0.01	-0.58	-0.1	0.39	-0.16	0.41	0.12	-0.23	-0.01	-0.27	0.06	-0.17	0.13	0.03
Retained Earnings	0.97	0.8	0.76	0.57	0.98	0.94	-0.26		-0.28	0.91	0.94	0.49	0.92	0.78	0.11	0.54	0.91	-0.5	0.83	0.98	0.92	0.45	0.89	0.94	0.75	0.54
Accounts Payable	-0.22	-0.25	-0.05	-0.19	-0.22	-0.15	0.12	-0.28		-0.3	-0.19	-0.14	-0.3	-0.21	0.41	-0.11	-0.33	0.34	-0.2	-0.26	-0.13	0.06	-0.2	-0.2	0.02	0.05
Cash	0.85	0.61	0.71	0.61	0.86	0.85	-0.59	0.91	-0.3		0.79	0.63	0.77	0.86	0.2	0.35	0.8	-0.56	0.69	0.89	0.74	0.54	0.68	0.83	0.57	0.41
Non Current Assets Total	0.99	0.86	0.68	0.63	0.98	0.96	-0.04	0.94	-0.19	0.79		0.27	0.9	0.69	0.26	0.58	0.84	-0.25	0.91	0.95	0.92	0.44	0.93	0.97	0.86	0.49
Non Currrent Assets Other	0.33	0.2	0.5	0.23	0.33	0.43	-0.57	0.49	-0.14	0.63	0.27		0.37	0.66	0.07	0.21	0.42	-0.86	0.31	0.38	0.44	0.65	0.12	0.26	0.14	0.57
Cash And Short Term Investments	0.92	0.9	0.65	0.36	0.9	0.86	-0.01	0.92	-0.3	0.77	0.9	0.37		0.61	0.11	0.79	0.88	-0.44	0.9	0.91	0.89	0.45	0.89	0.88	0.76	0.44
Net Receivables	0.74	0.43	0.78	0.69	0.74	0.79	-0.58	0.78	-0.21	0.86	0.69	0.66	0.61		0.39	0.21	0.73	-0.48	0.63	0.77	0.59	0.64	0.54	0.74	0.56	0.26
Common Stock Shares Outstanding	0.24	0.13	0.16	0.45	0.2	0.4	-0.1	0.11	0.41	0.2	0.26	0.07	0.11	0.39		0.12	0.08	0.36	0.39	0.22	0.13	0.7	0.16	0.31	0.4	-0.07
Non Current Liabilities Total	0.56	0.82	0.4	-0.09	0.51	0.53	0.39	0.54	-0.11	0.35	0.58	0.21	0.79	0.21	0.12		0.53	-0.32	0.75	0.53	0.62	0.43	0.58	0.5	0.6	0.35
Other Current Assets	0.89	0.77	0.63	0.56	0.88	0.84	-0.16	0.91	-0.33	0.8	0.84	0.42	0.88	0.73	0.08	0.53		-0.46	0.81	0.92	0.8	0.4	0.86	0.86	0.65	0.39
Other Stockholder Equity	-0.3	-0.3	-0.45	0.02	-0.31	-0.31	0.41	-0.5	0.34	-0.56	-0.25	-0.86	-0.44	-0.48	0.36	-0.32	-0.46		-0.25	-0.35	-0.44	-0.29	-0.14	-0.21	-0.07	-0.54
Total Liab	0.89	0.92	0.54	0.58	0.85	0.9	0.12	0.83	-0.2	0.69	0.91	0.31	0.9	0.63	0.39	0.75	0.81	-0.25		0.85	0.84	0.59	0.83	0.86	0.82	0.46
Total Current Assets	0.99	0.8	0.71	0.62	0.99	0.96	-0.23	0.98	-0.26	0.89	0.95	0.38	0.91	0.77	0.22	0.53	0.92	-0.35	0.85		0.89	0.46	0.94	0.97	0.78	0.45
Good Will	0.92	0.84	0.6	0.48	0.91	0.92	-0.01	0.92	-0.13	0.74	0.92	0.44	0.89	0.59	0.13	0.62	0.8	-0.44	0.84	0.89		0.46	0.88	0.88	0.76	0.73
Common Stock Total Equity	0.46	0.4	0.41	0.42	0.42	0.61	-0.27	0.45	0.06	0.54	0.44	0.65	0.45	0.64	0.7	0.43	0.4	-0.29	0.59	0.46	0.46		0.3	0.46	0.46	0.32
Short Term Investments	0.95	0.82	0.59	0.53	0.95	0.88	0.06	0.89	-0.2	0.68	0.93	0.12	0.89	0.54	0.16	0.58	0.86	-0.14	0.83	0.94	0.88	0.3		0.94	0.81	0.42
Property Plant And Equipment Gross	0.99	0.79	0.68	0.65	0.99	0.96	-0.17	0.94	-0.2	0.83	0.97	0.26	0.88	0.74	0.31	0.5	0.86	-0.21	0.86	0.97	0.88	0.46	0.94		0.82	0.37
Short Term Debt	0.83	0.82	0.74	0.47	0.81	0.82	0.13	0.75	0.02	0.57	0.86	0.14	0.76	0.56	0.4	0.6	0.65	-0.07	0.82	0.78	0.76	0.46	0.81	0.82		0.35
Intangible Assets	0.48	0.51	0.27	0.24	0.47	0.55	0.03	0.54	0.05	0.41	0.49	0.57	0.44	0.26	-0.07	0.35	0.39	-0.54	0.46	0.45	0.73	0.32	0.42	0.37	0.35

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

United Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Other Current Liab	39.6M	319.2M	301.6M	339.1M	398.8M	418.7M
Total Current Liabilities	463M	323.3M	305.4M	343.2M	804.4M	844.6M
Total Stockholder Equity	2.8B	3.4B	4.0B	4.8B	6.0B	6.3B
Property Plant And Equipment Net	738.5M	731.6M	780.9M	861.5M	1.0B	1.1B
Net Debt	111.6M	61.3M	(94.8M)	(161.2M)	(507.7M)	(482.3M)
Retained Earnings	3.3B	3.8B	4.3B	5.0B	6.0B	6.3B
Accounts Payable	23.1M	9.9M	4.1M	3.8M	5.6M	10.2M
Cash	738.4M	738.7M	894.8M	961.2M	1.2B	1.3B
Non Current Assets Total	2.0B	2.4B	2.8B	2.7B	3.6B	3.8B
Non Currrent Assets Other	154.6M	169.9M	108.2M	114.3M	151.8M	91.5M
Cash And Short Term Investments	2.3B	3.0B	3.6B	4.2B	3.0B	3.1B
Net Receivables	151.4M	157.4M	198.7M	220.4M	278.9M	292.8M
Common Stock Shares Outstanding	43.8M	44.6M	47.3M	48.5M	49.7M	50.7M
Liabilities And Stockholders Equity	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Non Current Liabilities Total	670M	896.5M	904.8M	904.6M	377.8M	269.4M
Other Current Assets	133.8M	88.3M	100.4M	219.2M	166.2M	174.5M
Other Stockholder Equity	(531.3M)	(430.5M)	(333.8M)	(190.8M)	(30.2M)	(28.7M)
Total Liab	1.1B	1.2B	1.2B	1.2B	1.2B	1.2B
Total Current Assets	1.9B	2.2B	2.3B	3.4B	3.6B	3.7B
Short Term Investments	747.5M	1.1B	1.0B	1.9B	1.8B	1.9B
Property Plant And Equipment Gross	738.5M	731M	1.1B	1.2B	1.5B	1.5B
Intangible Assets	130.3M	130.1M	16.6M	16.5M	80.5M	84.5M
Other Liab	67M	79.4M	104.8M	76.8M	88.3M	60.5M
Other Assets	293.8M	1.6B	370.1M	413.5M	475.5M	284.7M
Inventory	93.4M	86.5M	93.8M	102M	111.8M	55.9M
Property Plant Equipment	738.5M	731.6M	780.9M	861.5M	990.7M	1.0B
Net Tangible Assets	2.6B	3.2B	3.9B	4.8B	5.5B	5.7B
Retained Earnings Total Equity	3.3B	3.8B	4.3B	5.0B	5.8B	6.1B

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against United Stock

0.66	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.66	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.63	MTEM	Molecular Templates	Pair Corr
0.61	NKTX	Nkarta Inc	Pair Corr
0.61	TCHH	Trustcash Holdings	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC